MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued
Federico Fellini's LSD Journey: How It Inspired Some Of The Greatest Films Of All Time
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
LSD Therapy Recent News
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections
80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial
LSD's Impact On The Body's Cannabinoid And Microorganisms Systems, New Study Sheds Light
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
LSD Microdosing Yields Positive Outcomes In Phase 1 Study, More Trials On Depression & Existential Distress
Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
Using LSD To Treat Anxiety Is Showing Some Encouraging Findings In A Clinical Trial
Connecting To Nature Through Psychedelics